1-Deamino-8-D-Arginine Vasopressin in the Treatment of Non-Haemophilic Patients with Acquired Factor VIII Inhibitor
作者:
M. Muhm,
N. Grois,
P. Kier,
A. Stümpflen,
P. Kyrle,
I. Pabinger,
P. Bettelheim,
W. Hinterberger,
K. Lechner,
期刊:
Pathophysiology of Haemostasis and Thrombosis
(Karger Available online 1990)
卷期:
Volume 20,
issue 1
页码: 15-20
ISSN:1424-8832
年代: 1990
DOI:10.1159/000216100
出版商: S. Karger AG
关键词: Acquired haemophilia;Factor VIII inhibitor;1-Deamino-8-D-arginine vasopressin;Human factor VIII concentrate
数据来源: Karger
摘要:
1-Deamino-8-.D-arginine vasopressin (DDAVP) was administered to 3 patients with spontaneous factor VIII inhibitors. In 2 patients with baseline factor VIII levels above 1 %, a marked increase of factor VIII activity after DDAVP infusion could be observed. No rise of factor VIII activity after DDAVP was seen in the 3rd patient with a baseline factor VIII level of less than 1 %. Daily infusion of DDAVP resulted in a reduction of the efficacy, but the full effect could be retained when DDAVP was given at 48-hour intervals. The effect of DDAVP infusion on factor VIII levels in the 2 responding patients was superior to the treatment with 30 U/kg factor VIII concentrate and approximately equivalent to infusion of 45 U/kg factor VIII concentrate. DDAVP may be a useful and less expensive treatment for patients with acquired factor VIII inhibitors and a baseline factor VIII level of more than 1 %.
点击下载:
PDF
(1769KB)
返 回